PMID: 11921443Mar 29, 2002Paper

A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics

Proteomics
Daniel I R SpencerK A Chester

Abstract

Antibodies are highly specific recognition molecules which are increasingly being applied to target therapy in patients. One type of developmental antibody-based therapy is antibody directed enzyme prodrug therapy (ADEPT) for the treatment of cancer. In ADEPT, an antibody specific to a tumor marker protein delivers a drug-activating enzyme to the cancer. Subsequent intravenous administration of an inactive prodrug results in drug activation and cytotoxicity only within the locale of the tumor. Pilot clinical trials with chemical conjugates of the prodrug activating enzyme carboxypeptidase G2 (CPG2) chemically conjugated with an antibody to and carcinoembryonic antigen (CEA), have shown that CPG2-mediated ADEPT is effective but limited by formation of human antibodies to CPG2 (HACA). We have developed a recombinant fusion protein (termed MFE-CP) of CPG2 with an anti-CEA single chain Fv antibody fragment and we have developed methods to address the immunogenicity of this therapeutic. A HACA-reactive discontinuous epitope on MFE-CP was identified using the crystal structure of CPG2, filamentous phage technology and surface enhanced laser desorption/ionization affinity mass spectrometry. This information was used to create a functi...Continue Reading

Citations

Mar 12, 2004·Drug Discovery Today·Arthur J ChirinoShannon A Marshall
Mar 24, 2004·Nature Reviews. Microbiology·Nigel P Minton
Aug 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·Masanori OndaIra Pastan
Sep 13, 2011·Protein Engineering, Design & Selection : PEDS·Margaret E AckermanK Dane Wittrup
Aug 31, 2004·Journal of Clinical Pathology·K A SmithJ Greenman
Feb 17, 2011·Immunotherapy·Carima AndradyKerry A Chester
Nov 1, 2005·Expert Review of Clinical Immunology·Kerry A ChesterAstrid Mayer
Oct 27, 2004·Expert Opinion on Biological Therapy·Kenneth D BagshaweRichard H J Begent
Jul 22, 2006·Expert Opinion on Biological Therapy·D K Wilkins, A Mayer
Jul 23, 2003·Journal of Cellular Biochemistry·Qing-Yu He, Jen-Fu Chiu
Sep 15, 2012·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Xiaobo LiuHiroshi Ueda
Oct 16, 2016·Expert Opinion on Biological Therapy·Surinder K Sharma, Kenneth D Bagshawe
Aug 23, 2003·The Journal of Biological Chemistry·Holger A LindnerRobert Ménard
Jul 31, 2003·British Journal of Cancer·D R NewellUNKNOWN Cancer Research UK Phase I/II Clinical Trials Committee
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·K Alexander Papp
Mar 11, 2004·The Journal of Peptide Research : Official Journal of the American Peptide Society·P FuJ D Wade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.